| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 192,8 M € | +44.8% | 133,2 M € | +48.3% | 89,8 M € | +31.8% | 68,1 M € | +15.0% | 59,2 M € | +14.5% | 51,7 M € | +31.0% | 39,5 M € | +41.7% | 27,9 M € | +15.1% | 24,2 M € | +12.7% | 21,5 M € | +1.1% | 21,3 M € | +44.1% | 14,8 M € | -29.6% | 21,0 M € | +1.7% | 20,6 M € | +10.6% | 18,6 M € | +9.8% | 17,0 M € | -2.3% | 17,4 M € | +0.7% | 17,2 M € | -10.4% | 19,2 M € | |
| EBITDA | 4,7 M € | +22.9% | 3,8 M € | +33.7% | 2,9 M € | +39.3% | 2,1 M € | -12.5% | 2,4 M € | +159.9% | 908,3 k € | -27.0% | 1,2 M € | -14.4% | 1,5 M € | -37.1% | 2,3 M € | +154.3% | 909,6 k € | -43.1% | 1,6 M € | +283.2% | 417,2 k € | -70.1% | 1,4 M € | -67.6% | 4,3 M € | +54.9% | 2,8 M € | +59.1% | 1,7 M € | -16.8% | 2,1 M € | +9661.6% | -22,0 k € | -100.8% | 2,9 M € | |
| Operating profit | 4,4 M € | +22.6% | 3,6 M € | +43.4% | 2,5 M € | +33.9% | 1,9 M € | -16.2% | 2,2 M € | +187.4% | 780,4 k € | -36.6% | 1,2 M € | -9.3% | 1,4 M € | -40.2% | 2,3 M € | +197.6% | 763,3 k € | -50.6% | 1,5 M € | +326.2% | 362,6 k € | -72.6% | 1,3 M € | -68.2% | 4,2 M € | +58.6% | 2,6 M € | +58.7% | 1,7 M € | -17.3% | 2,0 M € | +2111.5% | -99,5 k € | -103.5% | 2,8 M € | |
| Profit/loss | 2,8 M € | +15.3% | 2,4 M € | +31.9% | 1,8 M € | +57.8% | 1,2 M € | -26.7% | 1,6 M € | +254.0% | 445,5 k € | -44.3% | 800,0 k € | +5.0% | 762,1 k € | -47.2% | 1,4 M € | +202.5% | 476,7 k € | -51.5% | 983,6 k € | +362.6% | 212,6 k € | -57.1% | 495,4 k € | -78.4% | 2,3 M € | +43.3% | 1,6 M € | +46.1% | 1,1 M € | -23.6% | 1,4 M € | +347.7% | -579,2 k € | -126.2% | 2,2 M € | |
| Equity | 8,3 M € | +1.5% | 8,2 M € | +1.6% | 8,1 M € | +1.1% | 8,0 M € | -4.8% | 8,4 M € | +6.9% | 7,8 M € | -8.6% | 8,6 M € | +10.3% | 7,8 M € | -33.3% | 11,7 M € | +14.1% | 10,2 M € | +4.9% | 9,8 M € | +11.2% | 8,8 M € | +2.5% | 8,6 M € | +1416.0% | 564,6 k € | +132.6% | -1,7 M € | +48.1% | -3,3 M € | +24.8% | -4,4 M € | +24.5% | -5,9 M € | -11.0% | -5,3 M € | |
| Total assets | 94,1 M € | +47.0% | 64,0 M € | +78.6% | 35,9 M € | +21.1% | 29,6 M € | +37.0% | 21,6 M € | -38.2% | 35,0 M € | +16.5% | 30,0 M € | +28.5% | 23,3 M € | +7.4% | 21,7 M € | +12.2% | 19,4 M € | +6.3% | 18,2 M € | +26.8% | 14,4 M € | +1.7% | 14,1 M € | +7.3% | 13,2 M € | +11.5% | 11,8 M € | -9.8% | 13,1 M € | +4.5% | 12,5 M € | +22.6% | 10,2 M € | +30.3% | 7,8 M € | |
| Cash | — | — | — | — | — | — | — | — | — | 0,0 € | -100.0% | 28,5 k € | -50.2% | 57,2 k € | -49.9% | 114,3 k € | +6098.8% | 1,8 k € | -99.6% | 485,3 k € | +65.4% | 293,5 k € | -76.0% | 1,2 M € | +51.9% | 805,5 k € | -62.9% | 2,2 M € | ||||||||||
| Debts | 85,7 M € | +54.3% | 55,5 M € | +102.5% | 27,4 M € | +27.5% | 21,5 M € | +63.1% | 13,2 M € | -51.1% | 27,0 M € | +25.9% | 21,4 M € | +37.7% | 15,6 M € | +56.1% | 10,0 M € | +12.5% | 8,9 M € | +19.7% | 7,4 M € | +65.6% | 4,5 M € | +9.3% | 4,1 M € | -63.4% | 11,2 M € | -9.9% | 12,4 M € | -18.4% | 15,2 M € | -3.4% | 15,7 M € | +5.1% | 14,9 M € | +14.2% | 13,1 M € | |
| Staff | 83,9 | 77,1 | 65,6 | 61,5 | 60,1 | 54,8 | 54,8 | 57,5 | 58,3 | 57,6 | 60,8 | 62,4 | 67,2 | 68,7 | 69,2 | 63,8 | 57,3 | 53,8 | 51 | |||||||||||||||||||
Public limited company · Braine-l'Alleud · incorporated on 08/08/1996 · 83,9 ETP
Public limited company profitable and well capitalised. Cash position declining (-100.0%).
Solid counterparty for a standard engagement.
DAIICHI SANKYO BELGIUM is a Public limited company incorporated in 1996. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Braine-l'Alleud. It employs on average 83,9 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette